Get the Stockscreener App
53.51
1.29%
-0.70
Crispr Therapeutics Ag stock is traded at $53.51, with a volume of 1.39M.
It is down -1.29% in the last 24 hours and down -4.40% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$54.21
Open:
$54.15
24h Volume:
1.39M
Relative Volume:
0.68
Market Cap:
$5.10B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-19.11
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-0.61%
1M Performance:
-4.40%
6M Performance:
-2.96%
1Y Performance:
+32.78%
1-Day Range:
$53.10
$54.75
1-Week Range:
$53.10
$57.99
52-Week Range:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.51 | 5.17B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | JP Morgan | Overweight |
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Meme Stocks: Will CRISPR Therapeutics AG benefit from geopolitical trendsJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Price Action: Is CRISPR Therapeutics AG showing insider buyingJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Aug Summary: Can CRISPR Therapeutics AG maintain its current growth rateEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
A Look At CRISPR Therapeutics (CRSP) Valuation As 2026 Gene Editing Milestones Come Into Focus - Sahm
Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story? - Sahm
CRISPR Therapeutics: Patience And Opportunity Through Volatility (NASDAQ:CRSP) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 251,163 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - sharewise.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
What's Driving the Market Sentiment Around CRISPR Therapeutics AG? - Benzinga
CRSP: Casgevy and next-gen gene editing platforms drive growth, with 2026 set as a pivotal year - TradingView — Track All Markets
2 Biotech Stocks That Could Soar This Year - Finviz
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? - Finviz
CRSP: Regulatory Submissions for CASGEVY Expected by Mid-2026 - GuruFocus
CRSP Outlines Strategic Goals and Milestones for 2026 - GuruFocus
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies - TipRanks
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
CRISPR Therapeutics Highlights Program Advancements - TradingView — Track All Markets
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next - TechStock²
CRISPR Therapeutics Reports Q3 2025 Financial Results - MSN
Avoiding Lag: Real-Time Signals in (CRSP) Movement - Stock Traders Daily
Is CRISPR Therapeutics (CRSP) Attractive After Recent Gene Editing Progress And Mixed Returns? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next - TechStock²
Revenue Check: How CRISPR Therapeutics AG stock valuations compare to rivalsStop Loss & Detailed Earnings Play Strategies - moha.gov.vn
Quarterly Risk: Is CRISPR Therapeutics AG stock a contrarian buyJuly 2025 Setups & Community Verified Watchlist Alerts - ulpravda.ru
Can CRISPR Therapeutics AG stock beat market expectations this quarterTreasury Yields & Real-Time Market Sentiment Reports - ulpravda.ru
Why global investors buy CRISPR Therapeutics AG (1CG) stock2025 Technical Patterns & Real-Time Market Sentiment Reports - ulpravda.ru
CRISPR Therapeutics AG CFO Sells Shares Under Trading Plan - TradingView — Track All Markets
Institutional Investors Are CRISPR Therapeutics AG's (NASDAQ:CRSP) Biggest Bettors and Were Rewarded After Last Week's US$529m Market Cap Gain - 富途牛牛
Is CRISPR Therapeutics AG stock positioned for long term growthVolatility Index Analysis & Free Discover Dynamic Stocks - ulpravda.ru
Aug Outlook: Why CRISPR Therapeutics AG (1CG) stock could be next leaderQuarterly Trade Report & Capital Efficient Trading Techniques - moha.gov.vn
Is CRISPR Therapeutics (CRSP) Attractively Priced After Recent Gene Editing Progress? - simplywall.st
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - sharewise.com
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 8.7%Still a Buy? - MarketBeat
Chardan maintains a buy recommendation on CRISPR Therapeutics AG (CRSP) - MSN
Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing CRISPR Therapeutics (CRSP) Valuation As Investor Interest Returns - simplywall.st
Assessing CRISPR Therapeutics' (CRSP) Valuation After Recent Share Price Volatility - Yahoo Finance
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Crispr Therapeutics: Prospects For 2026Why I Believe Casgevy Is Key (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG Stock Analysis and ForecastInsider Trading Compliance & Unlock Free Weekly Portfolio Checkups - earlytimes.in
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next - TechStock²
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):